Avalyn Pharma (NASDAQ:AVLN) Insider Fmr Llc Sells 53,454 Shares of Stock

Avalyn Pharma Inc. (NASDAQ:AVLN) insider Fmr Llc sold 53,454 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $30.21, for a total value of $1,614,845.34. Following the sale, the insider directly owned 2,056,081 shares of the company’s stock, valued at $62,114,207.01. This represents a 2.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Fmr Llc also recently made the following trade(s):

• On Monday, November 9th, Fmr Llc sold 175,000 shares of Avalyn Pharma stock. The stock was sold at an average price of $29.07, for a total transaction of $5,087,250.00.

Avalyn Pharma Price Performance

NASDAQ:AVLN opened at $30.59 on Friday. Avalyn Pharma Inc. has a one year low of $22.24 and a one year high of $40.17. The firm has a market capitalization of $1.36 billion and a P/E ratio of -1.34. The company has a fifty day moving average of $28.77. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.03). As a group, equities research analysts expect that Avalyn Pharma Inc. will post -3.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

AVLN has been the topic of a number of research reports. Morgan Stanley upped their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Raymond James Financial assumed coverage on shares of Avalyn Pharma in a research report on Friday, October 2nd. They set an “outperform” rating and a $60.00 price objective for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Avalyn Pharma in a research report on Wednesday. Finally, Wall Street Zen cut Avalyn Pharma from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVLN. Bank of New York Mellon Corp bought a new position in Avalyn Pharma during the 2nd quarter worth $1,321,000. Montanova Capital LLC acquired a new stake in shares of Avalyn Pharma during the second quarter worth $82,402,000. State Street Corp acquired a new stake in shares of Avalyn Pharma during the second quarter worth $10,501,000. Braidwell LP acquired a new stake in shares of Avalyn Pharma during the second quarter worth $26,382,000. Finally, Profund Advisors LLC bought a new stake in shares of Avalyn Pharma in the third quarter valued at about $668,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.